Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach is a paper indexed in PICO Portal from OpenAlex.
How many citations does Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach have?
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach has 24 citations in the OpenAlex counts PICO Portal stores.
When was Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach published?
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach has 2021 year in the PICO Portal index.
What is the open-access status of Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach?
Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach has diamond oa status in the PICO Portal index.
What is the DOI of Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach?
The DOI for Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach is on the source record.
What is the PMID of Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach?
The PMID for Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach is on the source record.
What is the OpenAlex record for Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach?
The OpenAlex for Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an <i>in silico</i> systems biology-based approach is on the source record.